Hugel Inc

Hugel Inc

145020 · KQ · Healthcare / Biotechnology

192,300.00KRW-4100.00 (-2.09%)

Price History

Full chart

Market Stats

Previous Close196,400.00
Open196,500.00
Day Range191,500.00 – 202,000.00
52-Week Range175,500.00 – 308,500.00
Volume42.88K
Market Cap1.95T
P/E (TTM)0.00
Forward P/E14.01
Dividend Yield0.00%
Beta0.56
50-Day Avg235,732.00
200-Day Avg248,008.00

About

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODaniel Chang
  • Employees620
  • Headquarters61-20, Sinbuk-ro, Chuncheon-si, South Korea, 24206, Korea
  • Websitehttps://www.hugel.co.kr

Leadership

  • Ms. Eva HuangManaging Director · b. 1984
  • Daniel ChangChief Executive Officer
  • Ms. Carrie C. StromPresident & Global CEO · b. 1978
  • J. T. KimMD & CFO
  • Ji-hye NohSenior Managing Director of Communication department
  • Mr. Soon-Woo KwonVP & Chief Production Officer · b. 1970
  • Jennifer RhoMD & Chief Strategy Officer
  • Jihye SongMD & Head of Cosmetics
  • Young Mahn YooMD & Chief Production Officer

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue40.35B65.07B124.19B182.09B182.39B204.57B211.04B245.15B281.68B319.70B373.05B425.11B
Growth (%)-+61.25%+90.87%+46.62%+0.17%+12.16%+3.16%+16.17%+14.90%+13.50%+16.69%+13.96%
Cost of Revenue12.00B26.56B29.79B39.97B51.01B60.62B62.25B64.35B62.82B73.54B85.87B91.63B
Gross Profit28.35B38.50B94.40B142.11B131.38B143.95B148.79B180.80B218.86B246.16B287.18B333.48B
Gross Margin70.27%59.18%76.01%78.05%72.03%70.37%70.50%73.75%77.70%77.00%76.98%78.45%
Operating Expense12.95B-29.83B31.15B39.75B45.76B75.86B71.37B84.57B124.40B139.94B139.38B132.63B
Operating Income15.40B68.34B63.25B102.36B85.63B68.09B77.42B96.23B94.46B106.22B147.80B200.85B
Operating Margin38.17%105.03%50.93%56.22%46.95%33.28%36.68%39.25%33.54%33.22%39.62%47.25%
EBITDA--------90.19B150.07B181.39B217.63B
EBITDA Margin--------32.02%46.94%48.62%51.19%
Net Income13.15B33.93B43.27B72.83B69.74B44.61B41.99B57.73B57.33B93.08B135.81B140.87B
Net Income Margin32.59%52.15%34.84%40.00%38.23%21.81%19.90%23.55%20.35%29.11%36.41%33.14%
R&D1.94B3.16B4.06B6.92B7.75B-15.74B12.62B15.08B11.02B9.21B11.70B
R&D as % of Total Revenue4.81%4.85%3.27%3.80%4.25%-7.46%5.15%5.35%3.45%2.47%2.75%
Interest Expense0000003.66B3.72B3.11B2.94B1.18B1.13B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%1.73%1.52%1.10%0.92%0.32%0.27%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets97.25B233.57B294.30B820.93B918.27B894.69B956.34B1.01T1.05T929.25B939.44B1.08T
Total Liabilities44.04B25.73B41.50B125.22B190.55B195.19B209.67B232.65B257.67B149.57B98.63B96.68B
Total Equity42.67B207.85B252.80B695.71B727.72B699.50B746.67B777.09B792.11B747.31B803.78B950.26B
Cash17.34B70.47B64.85B31.27B29.00B15.20B62.36B294.14B2.46M106.01B130.14B209.70B
Total Debt---79.57B82.93B90.20B92.32B-----
Net Debt-----71.33B27.71B-----

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow10.57B19.76B45.14B64.19B65.80B76.99B74.30B85.94B80.63B117.71B149.05B150.06B
Investing Cash Flow-7.80B-17.06B-53.91B-555.34B-32.22B-979.32M-25.30B180.13B-191.83B43.20B42.38B-
Financing Cash Flow-2.27B50.43B3.13B457.57B-35.63B-90.28B-1.84B-36.03B-51.37B-187.07B-172.07B-
Capital Expenditure5.87B13.11B16.09B6.34B9.10B12.28B16.98B23.88B32.82B40.56B33.31B29.52B
Free Cash Flow------29.13B37.54B35.60B77.15B115.74B120.54B
Dividends Paid-1.28M-------105.91M0-
FCF to OCF------39.21%43.68%44.15%65.55%77.65%80.33%
Dividend Paid to FCF---------0.14%0.00%-

Earnings

Report DateFeb 23, 2016May 16, 2016Aug 16, 2016Oct 26, 2016Feb 27, 2017Apr 27, 2017Jul 25, 2017Oct 25, 2017Feb 5, 2018Apr 25, 2018Aug 14, 2018Nov 14, 2018Feb 21, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Feb 14, 2020May 15, 2020Aug 14, 2020Nov 13, 2020Mar 18, 2021May 10, 2021Aug 17, 2021Nov 15, 2021Mar 17, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Feb 9, 2023May 15, 2023Aug 11, 2023Nov 14, 2023Mar 21, 2024May 9, 2024Aug 14, 2024Nov 14, 2024Mar 21, 2025May 8, 2025Aug 14, 2025Nov 14, 2025Mar 19, 2026May 7, 2026Aug 14, 2026Nov 3, 2026
EPS Estimate-1533.352069.932999.005130.003646.564588.124155.514359.463863.301510.351002.241144.941027.691098.891013.601125.56642.74840.991264.662052.951000.501448.401298.291600.43956.751247.051171.062473.88887.971539.951188.011813.291541.982030.153146.282886.342046.633293.163343.233516.222338.883018.812653.08
EPS Actual693.481667.003480.003715.003945.005382.005575.004481.003779.514925.001094.991687.981428.331067.99902.66798.99759.33478.003377.00782.00938.001446.001156.001614.00401.001213.001225.002221.0011.001375.001811.003346.001434.001856.003133.003570.003528.002640.003277.003269.003630.003567.003931.00-
Surprise-8.72%68.12%23.87%-23.10%47.59%21.51%7.83%-13.30%27.48%-27.50%68.42%24.75%3.92%-17.86%-21.17%-32.54%-25.63%301.55%-38.17%-54.31%44.53%-20.19%24.32%-74.94%26.78%-1.77%89.66%-99.56%54.85%17.60%181.65%-20.92%20.36%54.32%13.47%22.23%28.99%-0.49%-2.22%3.24%52.51%30.22%-
TimingPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hours-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market

Key Statistics & Ratios

Market Cap1.95T
Enterprise Value1.44T
Trailing P/E0.00
Forward P/E14.01
Price / Sales4.08
Price / Book1.91
Revenue (TTM)479.57B
Gross Profit (TTM)373.69B
EBITDA229.95B
Profit Margin32.94%
Operating Margin40.63%
Return on Equity16.53%
Return on Assets11.87%
Shares Outstanding10.80M
Shares Float5.24M
Beta0.56
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 8, 2020959692:319897